Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.42 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237732 | 1.00 | IGF1R (0.42) | IGF1RHMOX1CYP3A4TSHRMEN1 | |
| SCHEMBL1305581 | 1.00 | IGF1R (0.42) | IGF1RHMOX1CYP3A4TSHRMEN1 | |
| SCHEMBL17438169 | 0.87 | TSHR (0.48) | CYP3A4TSHRHTR3A | |
| SCHEMBL2368070 | 0.82 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL1986354 | 0.82 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL241160 | 0.82 | IGF1R (0.43) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL16070705 | 0.81 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL16070654 | 0.81 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL3175979 | 0.81 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 | |
| SCHEMBL3839205 | 0.81 | IGF1R (0.40) | IGF1RHMOX1MEN1KMT2ASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250065315-A1 | IRON COMPLEXES FOR ENANTIOSELECTIVE CIS DIHYDROXYLATION OF ALKENES | Laboratory for Synthetic Chemistry and Chemical Biology Limited (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4491270-A1 | IRON COMPLEXES FOR ENANTIOSELECTIVE CIS DIHYDROXYLATION OF ALKENES | The University of Hong Kong (HK) | 2025-01-15 | — | — | EP | disclosed |
| CN-119306769-A | Iron complexes for enantioselective cis dihydroxylation of olefins | 香港大学 | 2025-01-14 | — | — | CN | disclosed |
| CN-114560892-A | Chiral tridentate nitrogen phosphine ligand synthesized based on ferrocene skeleton and application thereof | 广东工业大学 | 2022-05-31 | — | — | CN | disclosed |
| EP-3192503-B1 | NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-08-14 | — | — | EP | disclosed |
| EP-2975022-B1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-20190054179-A1 | NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-10149911-B2 | Pharmaceutical composition containing hydroxamic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-12-11 | — | — | US | disclosed |
| US-10123990-B2 | Method for using novel hydroxamic acid derivative and antibacterial substance in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-11-13 | — | — | US | disclosed |
| US-9862676-B2 | Hydroxamic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-8053426-B2 | Such as 11-beta-[4-(1,2-Dihydroxyethyl)phenyl]-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17 alpha-pregna-4,9-dien-3-one or corresponding 4-(hydroxyacetyl)phenyl derivative thereof; endometriosis, myomas or hormone-dependent tumors, such as breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-11-08 | — | — | US | disclosed |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| EP-2081951-B1 | PROGESTERONE RECEPTOR ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-04-21 | — | — | EP | disclosed |
| EP-2081951-B1 | PROGESTERONE RECEPTOR ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080200440-A1 | Progesterone receptor antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200440-A1 | Progesterone receptor antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200440-A1 | Progesterone receptor antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008079836-A2 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008058767-A1 | PROGESTERONE RECEPTOR ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10149911-B2 | Pharmaceutical composition containing hydroxamic acid derivative or salt thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGLN2, HAAO | IGF1R 4702/4885HMOX1 476/4885CYP3A4 2841/4885 |
| US-20080200440-A1 | Progesterone receptor antagonists | PGR, PGRMC2, GNRHR | IGF1R 405/4885HMOX1 2976/4885CYP3A4 469/4885 |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F5 | IGF1R 1985/4885HMOX1 3323/4885CYP3A4 343/4885 |
| US-20250065315-A1 | IRON COMPLEXES FOR ENANTIOSELECTIVE CIS DIHYDROXYLATION OF ALKENES | SQLE, NFE2L2, FECH | IGF1R 4549/4885HMOX1 7/4885CYP3A4 127/4885 |
| US-20190054179-A1 | NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | HAAO, HPD, HCAR2 | IGF1R 4027/4885HMOX1 94/4885CYP3A4 2793/4885 |
| US-10123990-B2 | Method for using novel hydroxamic acid derivative and antibacterial substance in combination | EGLN2, NGLY1, NAAA | IGF1R 3989/4885HMOX1 305/4885CYP3A4 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.